Breakthrough status for Pfizer/Merck’s avelumab combo
Merck and Pfizer’s avelumab has picked up its second breakthrough therapy status in the US, this time for use in combination with Inlyta for treatment-naïve patients with advanced renal cell carcinoma (RCC).
Read More
